Published: 07-01-2021

We added 17,200 abstracts to our database throughout the year, a total of 6,188 were published in 2020.

 

Papers added to our database this year (published any year)

 

2,062 economic evaluations and 2,493 mortality studies were added to our database in 2020, which were published in 2019.

7% of abstracts included utility value data. With 151 new tools being added to our ontology, 54 of which assessed quality of life in caregivers of children. Some of the newly added tools are listed below:

 

Social Appearance Anxiety Scale (SAAS)	Fruit And Vegetable VAriety index (FAVVA).	Occupational Value Assessment questionnaire
Self-Assessment Manikin scale	Fatigue Symptom Inventory	Relatives' Stress scale
Ryff's Psychological Wellbeing Scale	General symptom Questionnaire, GSQ	Fami-Life questionnaire
Boston Bowel Preparation Scale (BBPS) score	Readiness for Hospital Discharge Scale (RHDS)	brief parenting scale (PS-7)
Functional Difficulties Questionnaire	Charleston Psychiatric Outpatient Satisfaction Scale CPOSS	Family Assessment Device (GF-FAD)
Heartland Forgiveness Scale	Health Care Relationship (HCR) Trust scale	Parent Report of Children's Abilities-Revised (PARCA-R)
Interpersonal Reactivity Index-C	Patient's Questionnaire on Participation in Discharge Planning	Cochlear Implant Quality of Life (CIQOL)
Psychosocial Adjustment and Role Skills Scale	Stress Response Questionnaire (SRQ)	Eustachian Tube Dysfunction Questionnaire (ETDQ-7)
Body Awareness Questionnaire	Kasari Frequency Intensity Time (FIT) index	Women's Ischemia Symptom Questionnaire (WISQ)
Adult Dispositional Hope Scale	Workplace Activity Limitations Scale (WALS)	Adolescent Pediatric Pain Tool

 

69 new interventions were added from January to September, all are listed below:

 

Semaglutide	Guadecitabine	Ianalumab	Tucatinib	Zolbetuximab	Moxetumomab pasudotox
Ipragliflozin	Pracinostat	Caplacizumab	Apabetalone	Opicinumab	Ivosidenib
Ertugliflozin	Lobaplatin	Utidelone	Peficitinib	Pyrotinib	Utomilumab
Praliciguat	B-cell antagonists	Zanubrutinib	Dalantercept	Enfortumab vedotin	Orvepitant
Nerinetide	HER-3 inhibitors	Emicizumab	Afuresertib	Guselkumab	Tislelizumab
Avibactam	Focal adhesion kinase inhibitors	Brigatinib	Poziotinib	Ripretinib	Surufatinib
Letermovir	Palmitoylethanolamide	Anifrolumab	Roniciclib	Polatuzumab Vedotin	Tarextumab
Glecaprevir	Icodextrin	Teprotumumab	Depatuxizumab mafodotin	Ibalizumab	Tirabrutinib
pibrentasvir	Pitolisant	Alisertib	Clazosentan	Lazertinib	Omadacycline
Dengue vaccine	Emibetuzumab	Patritumab	Mogamulizumab	Pamrevlumab
COVID-19 vaccine	imidafenacin	Defactinib	Lorlatinib	Olaptesed pegol
Melflufan	Darvadstrocel	Brentuximab vedotin	Enasidenib	Lanadelumab

 

 

550 abstracts added to Heoro focused on COVID-19, which was the only disease added to our ontology list. Cost and recourse use and mortality studies were the most common, as seen in figure 1.

 

Figure 1 - Study types of abstracts added to HEORO which focused on COVID-19

 

 

Papers added to our database only published in 2020

 

The most common study type was cost and resource use (2180 publications), followed by mortality studies (1534 publications), PRO studies (1305 publications) and Economic models (991 publications). This is represented in Figure 2.

Regarding study methodology, we added 839 abstracts of randomized controlled trials and 840 systematic literature reviews. 

 

 

Figure 2 - study type of papers published in 2020 on Heoro

 

Abstracts originated from 133 countries, with the USA (2059 publications) and the United Kingdom (1015 publications) being the highest, as seen in Figure 3.

 

Most abstracts were from Europe (2600 publications) followed by North America (2441), Asia (833 publications), Africa (328 publications) and South America (275 publications).

 

Figure 3 - abstracts by country added to Heoro

 

Finally, the abstracts most commonly reported on adult populations (figure 4). 

 

 

Figure 4 - abstracts published in 2020 by study population

 

 

 

Here's to an even better 2021 on HEORO.com!

 

 

Holly Gould 

Researcher